SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme

SapC-DOPS 纳米囊泡用于治疗多形性胶质母细胞瘤

• 批准号: 8917034
• 负责人: XIAOYANG QI
• 金额: $ 94.85万
• 依托单位: BEXION PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-25 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8917034
• 关键词: Activator Appliances; Affinity; Animal Model; Animals; Antineoplastic Agents; Behavioral; Biochemical; Biological Assay; Biological Markers; Brain Neoplasms; Catabolism; Cell Death; Cell surface; Cells; Ceramides; Characteristics; Chemistry; Clinical; Clinical Trials; Data; Diagnosis; Diagnostic; Dose; Drug Formulations; Drug Kinetics; Genetic; Genetic Markers; Glioblastoma; Glioma; Glucosylceramides; Goals; Grant; Growth; Health; Heterogeneity; Human; Implant; Investigational Drugs; Investigational New Drug Application; Link; Mediating; Membrane; Methods; Modeling; Molecular; Morbidity - disease rate; Mus; Normal Cell; Nude Mice; Outcome; Patients; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Phosphatidylserines; Phospholipids; Plasmids; Predisposition; Primates; Procedures; Production; Property; Proteins; Proteolipids; Protocols documentation; Qualifying; Radiosurgery; Research; Risk; Rodent; Safety; Small Business Innovation Research Grant; Solid Neoplasm; Sphingolipid Activator Proteins; Sphingolipids; Surface; Techniques; Technology; Testing; Therapeutic; Toxic effect; Tumor Bank; Tumor-Derived; Xenograft Model; analytical method; annexin A5; beta-Glucosidase Stimulating Protein; cancer cell; cell bank; chemotherapy; differential expression; drug candidate; effective therapy; efficacy trial; expression vector; glioma cell line; improved; in vivo; innovation; intravenous administration; killings; lysosomal proteins; meetings; nanovesicle; neoplastic cell; neovasculature; nonhuman primate; novel; oncology; phase 1 study; phase II trial; pre-clinical; preclinical study; response; scale up; success; targeted imaging; treatment strategy; tumor; tumor growth

DESCRIPTION (provided by applicant): Our goal is to develop a new molecular entity with a novel mechanism of action for targeting and eliminating glioblastoma multiforme (GBM, high grade glioma), a deadly and invasive brain tumor with no effective treatment. Of the 12,000 patients expected to be diagnosed with GBM this year, most will succumb within a year. There is an urgent demand for an efficacious anti-glioma drug. We are developing a new class of therapeutic proteolipid nanovesicle that can target and destroy glioma tumors. Composed of the small lysosomal sphingolipid activator protein saposin C (SapC, 80 aa) and the phospholipid dioleoylphosphatidylserine (DOPS); the stable 200 nm SapC-DOPS nanovesicles (clinical formulation is called BXQ-350) have unusually high affinity for phosphatidylserine-enriched membrane surfaces that occur widely in many types of tumor cells and tumor neovasculature. Consistent with sphingolipid activator function, BXQ-350 appear to selectively induce tumor cells to undergo ceramide-mediated cell death, apparently sparing non-tumor cells. In Phase I of this proposal, we demonstrated the feasibility of using SapC-DOPS to target and kill intracranial gliomas. Intravenous administration of SapC-DOPS in mice with orthotopically implanted gliomas resulted in dose-dependent improvement in survival. In Phase II, a GMP compliant formulation of SapC-DOPS (i.e., BXQ-350) was developed, and potency was confirmed in additional orthotopic preclinical GBM models. IND-enabling studies are in progress. Pharmacokinetics and toxicity studies thus far indicate favorable distribution and safety profiles in rodent and non-rodent studies. In this three-year Phase IIB proposal, the key objectives are to file the IND for BXQ-350, complete a Phase 1 clinical trial, and prepare for Phase 2. Recognizing that gliomas are highly heterogeneous, another objective is to identify and link biochemical factors (e.g., cell surface PS levels; genetic markers) to the degree of BXQ-350 tumoricidal activity. Understanding of these factors will improve dosing strategies and reduce the risk of variable therapeutic response. Specific Aims are: (1) Scale- up GMP production of BXQ-350; (2) File the IND and complete the Phase 1 clinical trial; and (3) Correlate susceptibility to killing by BXQ-350 with molecular and cellular characteristics of glioma cell lins (from a tumor bank). BXQ-350 offers an innovative and potentially powerful approach for slowing tumor growth and eliminating deep-seated brain tumors. Ultimately, we will progress this technology for treating other tumors and for developing tumor-targeted imaging diagnostics.

描述(申请人提供)：我们的目标是开发一种新的分子实体，具有新的作用机制，用于靶向和消除多形性胶质母细胞瘤(GBM，高级别胶质瘤)，这是一种致命的侵袭性脑瘤，没有有效的治疗方法。预计今年将有1.2万名患者被诊断为GBM，其中大多数将在一年内死亡。人们迫切需要一种有效的抗胶质瘤药物。我们正在开发一种新型的治疗性蛋白脂纳米胶囊，它可以靶向并摧毁胶质瘤肿瘤。由小分子溶酶体鞘磷脂激活蛋白皂苷C(SapC，80aa)和磷脂二油酰磷脂酰丝氨酸(DOPS)组成的稳定的200 nm SapC-DOPS纳米微囊(临床配方为BXQ-350)对富含磷脂酰丝氨酸的膜表面具有异常高的亲和力，广泛存在于许多类型的肿瘤细胞和肿瘤新生血管中。与鞘脂激活剂功能一致的是，BXQ-350似乎选择性地诱导肿瘤细胞经历神经酰胺介导的细胞死亡，显然节省了非肿瘤细胞。在这项建议的第一阶段，我们论证了使用SapC-DOPS靶向和杀伤颅内胶质瘤的可行性。SapC-DOPS静脉注射在原位种植的小鼠脑胶质瘤小鼠体内可导致剂量依赖性的生存改善。在第二阶段，开发了符合GMP的SapC-DOPS配方(即BXQ-350)，并在其他原位临床前GBM模型中证实了有效性。支持IND的研究正在进行中。到目前为止，药代动力学和毒性研究表明，在啮齿动物和非啮齿动物研究中，该药具有良好的分布和安全性。在这个为期三年的IIB阶段提案中，关键目标是提交BXQ-350的IND，完成第一阶段临床试验，并为第二阶段做准备。认识到胶质瘤具有高度异质性，另一个目标是识别生化因素(例如，细胞表面PS水平；遗传标记)并将其与BXQ-350的杀瘤活性程度联系起来。了解这些因素将改进给药策略，降低不同治疗反应的风险。具体目标是：(1)扩大BXQ-350的GMP生产；(2)提交IND并完成第一阶段临床试验；(3)将BXQ-350对BXQ-350的杀伤敏感性与(来自肿瘤银行的)胶质瘤细胞系的分子和细胞特性相关联。BXQ-350为减缓肿瘤生长和消除深层脑瘤提供了一种创新的、潜在的强大方法。最终，我们将把这项技术用于治疗其他肿瘤和开发肿瘤靶向成像诊断。